FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to oncology, and can be used to treat brain cancer. To this end, an amorphous solid dispersion, comprising N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine, is used in the treatment of local or metastatic brain cancer which is caused by excessive expression or amplification of ErbB2, wherein said N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine is administered as a tablet in a dose of 600 mg twice daily in combination with trastuzumab, capecitabine, bevacizumab, paclitaxel, or docetaxel. Also disclosed is the use of said compound after previous treatment of brain cancer, breast cancer, and also using another therapeutic agent.
EFFECT: group of inventions improves the effectiveness of treatment of brain cancer.
38 cl, 7 dwg, 6 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID DISPERSION | 2012 |
|
RU2648448C2 |
| POLYMORPHS OF ARRY-380, SELECTIVE INHIBITOR OF ERB2, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2012 |
|
RU2629116C2 |
| INHIBITORS OF TYPE ErbB INHIBITORS | 2006 |
|
RU2592703C9 |
| N4-PHENYLQUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS RECEPTOR TYROSINE KINASE TYPE ERBB INIHIBITORS FOR TREATING HYPERPROLIFERATIVE DISEASES | 2006 |
|
RU2428421C2 |
| HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR TREATING VESTIBULAR DISORDERS | 2009 |
|
RU2589846C2 |
| PYRAZOLAMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LEUCINE-REPEATING KINASE 2 | 2013 |
|
RU2637947C2 |
| HERBICIDE COMPOSITIONS | 2007 |
|
RU2472343C9 |
